Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.52 |
| ▸ | PPARD | Q03181 | 5/20 | 0.52 |
| ▸ | PPARG | P37231 | 6/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 2/20 | 0.46 |
| ▸ | PDE6D | O43924 | 1/20 | 0.46 |
| ▸ | PDE6A | P16499 | 1/20 | 0.46 |
| ▸ | PDE6G | P18545 | 1/20 | 0.46 |
| ▸ | PDE6B | P35913 | 1/20 | 0.46 |
| ▸ | PDE6C | P51160 | 1/20 | 0.46 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7372290 | 0.92 | PPARA (0.53) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL7372292 | 0.85 | PPARA (0.54) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL6943273 | 0.83 | PPARA (0.55) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL6940154 | 0.82 | PDE5A (0.47) | GAAPDE5A | |
| SCHEMBL27557551 | 0.81 | GAA (0.49) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL7368352 | 0.80 | PDE5A (0.50) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL7368350 | 0.80 | PDE5A (0.50) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL7369160 | 0.80 | PPARA (0.47) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL7360752 | 0.78 | PPARA (0.49) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL7364151 | 0.78 | PPARA (0.47) | PPARAPPARDPPARGPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | claimed |
| EP-1275386-A1 | SOLID DISPERSION WITH IMPROVED ABSORBABILITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-15 | — | — | EP | claimed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | claimed |
| CN-1305454-A | Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-07-25 | — | — | CN | claimed |
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| EP-1275386-A1 | SOLID DISPERSION WITH IMPROVED ABSORBABILITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| CN-1305454-A | Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-07-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | PPARA 1273/4885PPARD 1919/4885PPARG 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.